London midday: Stocks dip ahead of US inflation reading
London stocks had fallen into the red by lunchtime on Thursday, as investors awaited crucial US inflation data, which could ...
Europe midday: Shares stay in the red as focus turns to US CPI
European shares were lower on Thursday as investors turned their attention to US CPI data due later in the day.
GSK resolves Zantac cancer claims with a £1.7 billion settlement, boosting shares
The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GSK could still cause problems for the British firm: UBS. GlaxoSmithKline (GSK) saw its shares jump more than 6% after the ...
Pharmaceutical company GSK agrees to pay $2.3 bn in US settlements alleging Zantac cancer claims
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
GSK Stock Jumps as UK Drug Giant Resolves Most US Zantac Lawsuits
GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...
European Midday Briefing: Stocks on Hold as Investors Await U.S. Inflation Data
The German telecommunications group said Thursday that expectations of faster growth mean it aims to have 15 billion euros ($16.41 billion) in available cash by 2027 to either increase its stake in ...
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
Ealing Times2h
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer. Shares ...